Page last updated: 2024-11-06

phosphoramidic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphoramidic acid is a phosphorus-containing compound with the formula H2NPO(OH)2. It is a colorless solid that is soluble in water. Phosphoramidic acid is a key intermediate in the synthesis of various phosphorus-containing compounds, including pesticides, fertilizers, and pharmaceuticals. It is also a precursor to other important compounds, such as adenosine triphosphate (ATP), which plays a vital role in energy metabolism. The compound is often studied for its potential to act as a substrate or inhibitor in various enzymatic reactions, including those involving kinases and phosphatases. It is used in the synthesis of various phosphorus-containing compounds, such as pesticides, fertilizers, and pharmaceuticals.'

phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65107
CHEMBL ID121754
CHEBI ID15907
MeSH IDM0057093

Synonyms (18)

Synonym
h2nh2po3
2817-45-0
[p(nh2)o(oh)2]
amidodihydroxidooxidophosphorus
CHEBI:15907 ,
phosphoramidic acid
amidophosphoric acid
C02306
aminophosphonic acid
CHEMBL121754
9q189608gb ,
unii-9q189608gb
phosphorylamine
phosphoric monoamide
monoamidophosphate
monoamidophosphoric acid
DTXSID50182441
Q27098293

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Many of the phosphoramidates are less toxic than their phosphoramidothionate analogues, probably due to less favourable physical properties."( THE COMPARATIVE TOXICITY OF PHOSPHORAMIDOTHIONATES AND PHOSPHORAMIDATES TO SUSCEPTIBLE AND INSECTICIDE-RESISTANT HOUSEFLIES AND MOSQUITOS.
GEORGHIOU, GP; MARCH, RB; METCALF, RL; PRINTY, GE, 1964
)
0.24

Bioavailability

ExcerptReferenceRelevance
" Oligonucleotide phosphoramidates apparently are cell permeable, and they have a good bioavailability and biodistribution, while being non-toxic in mice at therapeutically relevant doses."( Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents.
Gryaznov, SM, 1999
)
0.3
" Optimization of the sequence, length, and bioavailability resulted in the selection of a 13-mer NPS oligonucleotide, GRN163, as a drug development candidate."( A novel telomerase template antagonist (GRN163) as a potential anticancer agent.
Akinaga, S; Asai, A; Chin, AC; Gryaznov, S; Harley, CB; Kusaka, H; Li, S; Oshima, Y; Piatyszek, M; Pongracz, K; Pruzan, R; Uochi, TA; Wunder, E; Yamamoto, Y; Yamashita, Y, 2003
)
0.32
" In vivo, these compounds show good bioavailability and efficient biodistribution to all major organs, while exerting acceptable toxicity at therapeutically relevant doses."( Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.
Gryaznov, SM, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides."( Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Attenni, B; Di Marco, A; Donghi, M; Fiore, F; Gardelli, C; Gennari, N; Giuliano, C; Harper, S; Laufer, R; Leone, JF; MacCoss, M; Marcucci, I; Meppen, M; Narjes, F; Olsen, DB; Pacini, B; Pucci, V; Rowley, M, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphoric acid derivative
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID233500The pKa value was measured at 31-P chemical shift changes due to protonation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Protonation of phosphoramide mustard and other phosphoramides.
AID233498The pKa value was measured at 15-N chemical shift changes due to protonation1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Protonation of phosphoramide mustard and other phosphoramides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (500)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (5.60)18.7374
1990's54 (10.80)18.2507
2000's199 (39.80)29.6817
2010's181 (36.20)24.3611
2020's38 (7.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.04 (24.57)
Research Supply Index6.29 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index103.05 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (43.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews28 (5.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other508 (94.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers [NCT00031616]Phase 1/Phase 20 participants Interventional2001-12-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]